About ViaCyte
ViaCyte is a company based in San Diego (United States) founded in 1999 was acquired by Vertex Pharmaceuticals in July 2022. ViaCyte has raised $389.03 million across 18 funding rounds from investors including CRISPR Therapeutics, Johnson & Johnson and Vertex Pharmaceuticals. The company has 126 employees as of December 31, 2022. ViaCyte operates in a competitive market with competitors including Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Sana Biotechnology and Semma Therapeutics, among others.
- Headquarter San Diego, United States
- Employees 126 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Viacyte, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$389.03 M (USD)
in 18 rounds
-
Latest Funding Round
$115 M (USD), Series D
Jun 09, 2021
-
Investors
CRISPR Therapeutics
& 21 more
-
Employee Count
126
as on Dec 31, 2022
-
Acquired by
Vertex Pharmaceuticals
(Jul 11, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of ViaCyte
Unlock access to complete
Unlock access to complete
Leadership Team
249 people
Software Development Team
218 people
Senior Team
136 people
Principal Team
61 people
Finance and Accounting
53 people
Operations Team
35 people
Legal and Compliance
34 people
Sales and Marketing
30 people
Unlock access to complete
Funding Insights of ViaCyte
ViaCyte has successfully raised a total of $389.03M across 18 strategic funding rounds. The most recent funding activity was a Series D round of $115 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ViaCyte
ViaCyte has secured backing from 22 investors, including venture fund and institutional investors. Prominent investors backing the company include CRISPR Therapeutics, Johnson & Johnson and Vertex Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Fund of funds focused on pre-seed and seed-stage companies
|
Locked | Locked | Locked | |
|
Biomedical investment financing and active management services.
|
Locked | Locked | Locked | |
|
Long-term private equity investments in transformational opportunities are pursued.
|
Locked | Locked | Locked |
Investor details for ViaCyte
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ViaCyte
Investment portfolio details for ViaCyte
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ViaCyte
Detailed financials for ViaCyte
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Viacyte Comparisons
Peer comparison for ViaCyte
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ViaCyte
ViaCyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Sana Biotechnology and Semma Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of small-molecule drugs
|
|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
Detailed competitors of ViaCyte
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Viacyte
Complete news archive for ViaCyte
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ViaCyte
ViaCyte was founded in 1999 and raised its 1st funding round 8 years after it was founded.
ViaCyte is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
ViaCyte is a funded company, having raised a total of $389.03M across 18 funding rounds to date.
As of Dec 31, 2022, the latest employee count at ViaCyte is 126.
ViaCyte was founded in 1999 in San Diego, United States, within the biotechnology sector. Operations center on advancing cell-based treatments for diabetes. The primary candidate, VC-01, involves pancreatic progenitor cells sourced from human pluripotent stem cells, which are placed in an implantable encapsulation device. Upon maturation post-implantation, insulin and regulatory factors are secreted by these cells in response to glucose levels, targeting sustained management without immunosuppression or related risks.
ViaCyte's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept.
ViaCyte has 22 investors. Key investors include CRISPR Therapeutics, Johnson & Johnson, Vertex Pharmaceuticals, W. L. Gore & Associates, and TPG.